Last edition
News about
IIL Inaugurates Greenfield Animal Vaccine Manufacturing Facility in Hyderabad
Indian Immunologicals Limited (IIL) has started construction of its new greenfield veterinary vaccine facility to manufacture the Foot and Mouth Disease Vaccine (FMD-Vac) as well as Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine (FMD-Vac) as well as Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine (FMD+HS-Vac) in Hyderabad.
Bristol Myers Squibb Acquires RayzeBio for USD 4.1 Billion
RayzeBio specializes in developing radioactive drugs targeting various tumors in organs such as the lung, pancreas, and liver.
Venus Remedies Secures Marketing Approval from Israel, Colombia for Two Oncology Drugs
Building on its international presence in the oncology space, Venus Remedies has secured marketing authorisation for docetaxel from Israel and cytarabine from Colombia.
Silo Pharma Gets Nod to Develop Ketamine Implant for Fibromyalgia
In collaboration with Sever Pharma Solutions, Silo's development partner, SP-26 is undergoing crucial analytical testing and pre-clinical trials.
Union Health Minister Launches Critical Care Blocks and Labs in Andhra Pradesh
The new facilities are poised to enhance Andhra Pradesh's healthcare infrastructure, providing a substantial response to health emergencies.
Eugia Pharma Specialities Ltd Gets USFDA Final Approval for Posaconazole Injection
The product is expected to be launched in December 2023. The approved product has an estimated market size of USD 25.4 million for the twelve months ending October 2023, according to IQVIA.
Sanjivani Paranteral Raises Funds through Issuance of Warrants & Preferential Allotment
The company also approved preferential allotment of 16,86,000 equity shares at Rs 135.10 per share, amounting to Rs 22.77 crores to non-promoter investors.
The product will be manufactured at Lupin’s Pithampur facility in India. Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site
PharmaBlock Sciences (Nanjing), Inc. has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and above) at its Zhejiang manufacturing site.
Under this strategic collaboration, Menarini India has obtained exclusive rights to market and distribute the dermo-cosmetic brands, EAU THERMALE AVÈNE and DUCRAY in India.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy